Hospital
Lallie Kemp Medical CTR
Lallie Kemp Medical CTR was paid $13.93M by Medicaid between Jan 2018 and Dec 2024, across 139 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoLALLIE KEMP MEDICAL CTR
INDEPENDENCE, LA 70443
INDEPENDENCE, LA 70443
33aNPI1083661409assigned 05/30/2006
33bProvider typeCritical Access Hospital
28Total paid$13.93M
24GClaims422,676
24DCodes billed139
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#2 of 40
Median peer was paid$3.19M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,248 | $1.38M | |
| 2019 | 54,040 | $1.51M | |
| 2020 | 44,007 | $1.26M | |
| 2021 | 73,870 | $2.72M | |
| 2022 | 72,600 | $2.93M | |
| 2023 | 85,728 | $2.80M | |
| 2024incomplete | 35,183 | $1.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 23,157 | 20,887 | $3.63M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 8,689 | 7,799 | $1.96M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 19,152 | 17,158 | $1.92M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 55,857 | 49,317 | $1.52M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.2% | 25,092 | 22,230 | $582K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.3% | 8,094 | 6,808 | $460K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 1,355 | 1,201 | $388K |
| 80053 | Comprehensive metabolic panel | 2.2% | 38,345 | 33,750 | $305K |
| 80061 | Lipid panel | 1.4% | 19,201 | 17,627 | $200K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 27,541 | 23,867 | $155K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 1,418 | 1,217 | $153K |
| 87536 | <1% | 2,071 | 1,875 | $132K |
127 more codes
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 813 | $128K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,816 | $128K |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,831 | $122K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,569 | $117K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,989 | $115K |
| 80050 | General health panel | <1% | 3,186 | $111K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,773 | $107K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,885 | $96K |
| 87428 | <1% | 3,528 | $92K | |
| 76830 | Ultrasound, transvaginal | <1% | 771 | $85K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,048 | $72K |
| 86360 | <1% | 1,960 | $70K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,405 | $69K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,389 | $57K |
| 86359 | <1% | 1,967 | $56K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 73 | $54K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,366 | $50K |
| 81025 | <1% | 7,791 | $50K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 857 | $50K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,827 | $49K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,365 | $43K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,988 | $42K |
| 83880 | <1% | 1,861 | $40K | |
| 81001 | <1% | 16,918 | $39K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 254 | $37K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,164 | $29K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,560 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 996 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 992 | $27K |
| 84484 | <1% | 3,571 | $26K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 528 | $24K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,062 | $24K |
| 85027 | <1% | 4,236 | $21K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 432 | $20K |
| 90686 | <1% | 1,654 | $20K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 28 | $20K |
| 80074 | <1% | 444 | $19K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 747 | $16K |
| 86357 | <1% | 587 | $16K | |
| 86355 | <1% | 587 | $16K | |
| 84153 | <1% | 1,133 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 692 | $16K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 47 | $14K |
| 82043 | <1% | 3,078 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 981 | $14K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 289 | $14K |
| 82570 | <1% | 3,217 | $13K | |
| 90674 | <1% | 865 | $12K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 263 | $12K |
| 84466 | <1% | 1,196 | $11K | |
| 90715 | <1% | 232 | $11K | |
| 90732 | <1% | 90 | $10K | |
| 82150 | <1% | 1,956 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 472 | $8K |
| 84403 | <1% | 463 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,424 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 140 | $8K |
| 0002A | <1% | 237 | $8K | |
| 0001A | <1% | 245 | $7K | |
| 80069 | <1% | 1,253 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 424 | $7K |
| 87522 | Neg quan hep c or qual rna | <1% | 167 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 165 | $6K |
| 86803 | <1% | 547 | $6K | |
| 83540 | <1% | 1,286 | $6K | |
| 87210 | <1% | 1,317 | $5K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 346 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 15 | $5K |
| 83605 | <1% | 581 | $4K | |
| 87081 | <1% | 602 | $4K | |
| 83970 | <1% | 174 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 204 | $4K |
| 86480 | <1% | 56 | $3K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $3K |
| 84100 | <1% | 1,324 | $3K | |
| 82728 | <1% | 348 | $3K | |
| 86592 | <1% | 814 | $3K | |
| 82947 | <1% | 1,040 | $2K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 87 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 46 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 74 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 343 | $2K |
| 90656 | <1% | 158 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 431 | $2K |
| 90670 | <1% | 13 | $2K | |
| 85610 | <1% | 647 | $1K | |
| 82962 | <1% | 693 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 302 | $1K |
| 82607 | <1% | 76 | $873.99 | |
| 92228 | <1% | 36 | $801.36 | |
| J1380 | Injection, estradiol valerate, up to 10 mg | <1% | 95 | $773.06 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 31 | $538.63 |
| 82550 | <1% | 117 | $500.90 | |
| 83001 | <1% | 27 | $427.34 | |
| 86705 | <1% | 40 | $424.72 | |
| 87340 | <1% | 41 | $372.76 | |
| 83735 | <1% | 89 | $355.10 | |
| 85730 | <1% | 95 | $286.79 | |
| 85379 | <1% | 37 | $285.04 | |
| 86756 | <1% | 14 | $222.46 | |
| 84439 | <1% | 39 | $219.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $212.47 |
| 81003 | <1% | 156 | $197.48 | |
| 91300 | <1% | 733 | $185.40 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 143 | $170.89 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 26 | $146.05 |
| 86706 | <1% | 15 | $128.88 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 18 | $119.84 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 37 | $114.74 |
| 87040 | <1% | 12 | $113.52 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 239 | $89.03 |
| J2704 | Injection, propofol, 10 mg | <1% | 604 | $88.59 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 251 | $87.93 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 21 | $76.23 |
| 84156 | <1% | 40 | $62.39 | |
| 90662 | 0% | 131 | $0.00 | |
| 84681 | 0% | 14 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 35 | $0.00 |
| 00000 | 0% | 653 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 38 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 276 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 83 | $0.00 |
| 90480 | 0% | 15 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 34 | $0.00 |
| 90694 | 0% | 16 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 21 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUTLER, MICHAEL (ACTING CEO)
| Provider | Location | Paid |
|---|---|---|
| Lallie Kemp Medical CTR | Independence, LA | $5.44M |
| Village Apothecary, INC. | Hot Springs, AR | $111K |
| Coleman Butler FT Smith, LLC | Fort Smith, AR | $52K |
| Village Apothecary INC | Hot Springs Village, AR | $30K |
| Village Apothecary INC | Hot Springs, AR | $30K |
| Coleman Butler FT Smith LLC | Fort Smith, AR | $28K |
| Clinton Butler | Clinton, AR | $11K |
| Beaverton Family Medicine LLC | Beaverton, AL | $3K |
| Village Apothecary, INC | Texarkana, AR | $0.00 |
| Compassionate Services, INC | Gilbert, AZ | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.